Hailong Tao

Dr. Hailong Tao


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 May 2024 in Journal of the American Heart Association
Verified
Journal Article
Open access
YPYing Peng
Ying Peng
ZLZhonggen Li
Zhonggen Li
JZJianchao Zhang
Jianchao Zhang
YDYunshu Dong
Yunshu Dong
CZChenglin Zhang
Chenglin Zhang
JDJianzeng Dong
Jianzeng Dong
Background: The only clinically approved drug that reduces doxorubicin cardiotoxicity is dexrazoxane, but its application is limited due to the risk of secondary malignancies. So, exploring alternative effective molecules to attenuate its cardiotoxicity is crucial. Colchicine is a safe and well‐tolerated drug that helps reduce the production of reactive oxygen species. High doses of colchicine have been reported to block the fusion of autophagosomes and lysosomes in cancer cells. However, the impact of colchicine on the autophagy activity within cardiomyocytes remains inadequately elucidated. Recent studies have highlighted the beneficial effects of colchicine on patients with pericarditis, postprocedural atrial fibrillation, and coronary artery disease. It remains ambiguous how colchicine regulates autophagic flux in doxorubicin‐induced heart failure. Methods and Results: Doxorubicin was administered to establish models of heart failure both in vivo and in vitro. Prior studies have reported that doxorubicin impeded the breakdown of autophagic vacuoles, resulting in damaged mitochondria and the accumulation of reactive oxygen species. Following the administration of a low dose of colchicine (0.1 mg/kg, daily), significant improvements were observed in heart function (left ventricular ejection fraction: doxorubicin group versus treatment group=43.75%±3.614% versus 57.07%±2.968%, P =0.0373). In terms of mechanism, a low dose of colchicine facilitated the degradation of autolysosomes, thereby mitigating doxorubicin‐induced cardiotoxicity. Conclusions: Our research has shown that a low dose of colchicine is pivotal in restoring the autophagy activity, thereby attenuating the cardiotoxicity induced by doxorubicin. Consequently, colchicine emerges as a promising therapeutic candidate to improve doxorubicin cardiotoxicity.

14 June 2023 in Immunity, Inflammation and Disease
Verified
Journal Article
Open access
YWYuzhen Wei
Yuzhen Wei
JXJunhui Xing
Junhui Xing
XSXin Su
Xin Su
XLXiangrao Li
Xiangrao Li
XYXiaofei Yan
Xiaofei Yan
HTHailong Tao
Hailong Tao
Background: Reperfusion therapy is the most effective approach to resolve coronary occlusion, but myocardial injury caused by excessive inflammation during myocardial ischemia–reperfusion will also pose a new threat to health. Our prior study revealed the expression pattern of interleukin‐38 (IL‐38) in the peripheral blood serum of patients with ischemic cardiomyopathy and the role of IL‐38 in acute myocardial infarction in mice. However, its role and potential mechanisms in myocardial ischemia/reperfusion injury (MIRI) remain to be determined.Methods and Results: The left anterior descending artery of C57BL/6 mice was transiently ligated to induce the MIRI model. We found that MIRI induced the expression of endogenous IL‐38, which was mainly produced by locally infiltrating macrophages. Overexpression of IL‐38 in C57BL/6 mice attenuated inflammatory injury and decreased myocardial apoptosis after myocardial ischemia–reperfusion. Furthermore, IL‐38 inhibited lipopolysaccharide‐induced macrophage inflammation in vitro. Cardiomyocytes cocultured with the supernatant of IL‐38‐ and troponin I‐treated macrophages showed a lower rate of apoptosis than controls.Conclusions: IL‐38 attenuates MIRI by inhibiting macrophage inflammation. This inhibitory effect may be partially achieved by inhibiting the activation of NOD‐like receptor pyrin domain‐related protein 3 inflammasome, resulting in decreased expression of inflammatory factors and reduced cardiomyocyte apoptosis.

1 January 2022 in Clinical and Applied Thrombosis/Hemostasis
Verified
Journal Article
Open access
BCBo-Wen Chen
Bo-Wen Chen
JLJia-Jing Liu
Jia-Jing Liu
JXJun-Hui Xing
Jun-Hui Xing
HLHeng-Dao Liu
Heng-Dao Liu
YWYu-Zhen Wei
Yu-Zhen Wei
HTHailong Tao
Hailong Tao
Background: High-density lipoprotein cholesterol (HDL-C) and monocytes are associated with coronary artery disease, and the ratio of monocytes to high-density lipoprotein (MHR) is associated with long-term adverse outcomes and the recurrence of atrial fibrillation. Currently, the trend of coronary heart disease proned to young people is becoming prominent. However, the relationship between MHR and in-stent restenosis (ISR) in patients with premature coronary heart disease (PCHD) has not been investigated. Therefore, we aimed to assess the relationship between MHR and ISR in patients with PCHD. Methods: We retrospectively included 257 patients (men ≤ 55 years old, women ≤ 65 years old) with PCHD who underwent drug-eluting stent implantation and follow-up coronary angiography at the First Affiliated Hospital of Zhengzhou University from September 2016 to September 2019. Patients were divided into ISR and non-ISR groups depending on their follow-up coronary angiography results. Relative clinical information was recorded and analyzed. A receiver operating characteristic curve analysis was used to determine the optimum pre-procedural MHR cutoff value to predict ISR. Results: Logistic regression analysis showed that MHR, smoking history, and fibrinogen were independent risk factors for ISR in patients with PCHD. The area under the receiver operating characteristic curve (AUC) of MHR was 0.750 (95% confidence interval, 0.695-0.820; P < .001), the cutoff value was 546.88, and the specificity and sensitivity were 65.2% and 78%, while the AUC of monocytes was 0.631 (95% confidence interval, 0.638-0.794; P < .001), the cutoff value was 590, and the specificity and sensitivity were 77.1% and 60.0%. Conclusion: MHR is an independent risk factor for ISR in patients with PCHD and showed a certain predictive value.

5 October 2022 in Clinical and Applied Thrombosis/Hemostasis
Verified
Journal Article
Open access
YZYu-Bin Zhang
Yu-Bin Zhang
HLHeng-Dao Liu
Heng-Dao Liu
JXJun-Hui Xing
Jun-Hui Xing
BCBo-Wen Chen
Bo-Wen Chen
YZYan-Yan Zhao
Yan-Yan Zhao
HTHailong Tao
Hailong Tao
Background: Percutaneous coronary intervention (PCI) is the main treatment option for acute coronary syndromes (ACS) often related to the progression and rupture of vulnerable plaques. While drug-eluting stents (DES) are now routinely used in PCI, drug-coated balloons (DCB) are a new strategy to PCI and their practice in the treatment of ACS with vulnerable plaques has not been reported. This study aimed to evaluate the safety and efficacy of DCB in ACS complicated with vulnerable plaque lesions. Methods: 123 patients were retrospectively analyzed and diagnosed with ACS and given PCI in our Cardiology Department from December 2020 to July 2022. Vulnerable plaques were confirmed by intravenous ultrasound (IVUS) in all patients. According to individual treatment plan, patients were entered into either DCB (n = 55) or DES (n = 68) groups. The results of coronary angiography and IVUS before and immediately after percutaneous coronary intervention were analyzed. The occurrence of major adverse cardiovascular events (MACE) and the results of coronary angiography were also evaluated during follow-up. Results: There were no significant differences in baseline clinical characteristics, preoperative minimal luminal diameter (MLD), and preoperative diameter stenosis (DS) between the two groups. Also, there were no differences in IVUS plaque burden (PB), vessel area, and lumen area in the two groups before and immediately after PCI. The efficacy analysis showed that immediately after PCI, the DCB group had smaller MLD and higher degrees of lumen stenosis than the DES group ( P < 0.05). However, during follow-up, no significant differences in MLD and DS were seen in two groups; relatively, late loss in luminal diameter(LLL)in the DCB group was smaller ( P<0.05). Safety analysis showed that during follow-up, 9 patients developed restenosis after DCB implantation while restenosis occurred in 10 patients with DES treatment, no statistical difference in the incidence of restenosis in the two groups. Besides, there was no statistical difference in the incidence of major adverse cardiac events(MACE)during hospitalization and follow-up in the DCB group (7.3% (4/55)) and the DES group (8.8% (6/68)). Conclusion: DCB is safe and effective for ACS complicated with vulnerable plaque and has an advantage over DES in LLL.

29 February 2024 in Journal of Cardiovascular Electrophysiology
Verified
Journal Article
Closed access
JLJiaju Li
Jiaju Li
KCKe Chen
Ke Chen
LHLiu He
Liu He
FLFangyuan Luo
Fangyuan Luo
XWXianqing Wang
Xianqing Wang
JDJianzeng Dong
Jianzeng Dong

31 January 2026 in International Journal of Medical Informatics
Verified
Journal Article
Closed access
PWPanji Wang
Panji Wang
YMYuan Meng
Yuan Meng
ZSZhaowei Sun
Zhaowei Sun
JLJiaju Li
Jiaju Li
HTHailong Tao
Hailong Tao